Nuclear Medicine Imaging in Dementia: A Practical Overview for Hospitalists

References

• . Silverman DH. Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging. J Nucl Med. 2004;45(4):594–607
   PubMed Web of Science ®Google Scholar
• . Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health. 1998;88(9):1337–1342
   PubMed Web of Science ®Google Scholar
• . Mukadam N, Sampson EL. A systematic review of the prevalence, associations and outcomes of dementia in older general hospital inpatients. Int Psychogeriatr. 2011;23(3):344–355
   PubMed Web of Science ®Google Scholar
• . Harwood DM, Hope T, Jacoby R. Cognitive impairment in medical inpatients. I: Screening for dementia—is history better than mental state? Age Ageing. 1997;26(1):31–35
   PubMed Web of Science ®Google Scholar
• . Joray S, Herrmann F, Mulligan R, Schnider A. Mechanism of disorientation in Alzheimer's disease. Eur Neurol. 2004;52(4):193–197
   PubMed Web of Science ®Google Scholar
• . Solomon PR, Murphy CA. Should we screen for Alzheimer's disease? A review of the evidence for and against screening Alzheimer's disease in primary care practice. Geriatrics. 2005;60(11):26–31
   PubMed Web of Science ®Google Scholar
• . McKeith IG, Dickson DW, Lowe J, ; Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65(12):1863–1872
   PubMed Web of Science ®Google Scholar
• . Waldemar G, Dubois B, Emre M, ; EFNS. Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol. 2007;14(1):e1–e26
   PubMed Web of Science ®Google Scholar
• . Inouye SK, Bogardus ST Jr, Vitagliano G, . Burden of illness score for elderly persons: risk adjustment incorporating the cumulative impact of diseases, physiologic abnormalities, and functional impairments. Med Care. 2003;41(1):70–83
   PubMed Web of Science ®Google Scholar
• . McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939–944
   PubMed Web of Science ®Google Scholar
• . Knopman DS, DeKosky ST, Cummings JL, . Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56(9):1143–1153
   PubMed Web of Science ®Google Scholar
• . Dubois B, Feldman HH, Jacova C, . Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6(8):734–746
   PubMed Web of Science ®Google Scholar
• . Foster NL. A new framework for the diagnosis of Alzheimer's disease. Lancet Neurol. 2007;6(8):667–669
   PubMed Web of Science ®Google Scholar
• . Petrella JR, Coleman RE, Doraiswamy PM. Neuroimaging and early diagnosis of Alzheimer disease: a look to the future. Radiology. 2003;226(2):315–336
   PubMed Web of Science ®Google Scholar
• . Román GC, Tatemichi TK, Erkinjuntti T, . Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993;43(2):250–260
   PubMed Web of Science ®Google Scholar
• . van der Flier WM, Scheltens P. Epidemiology and risk factors of dementia. J Neurol Neurosurg Psychiatry. 2005;76( suppl 5):v2–v7
   PubMed Web of Science ®Google Scholar
• . Buschke H, Kuslansky G, Katz M, . Screening for dementia with the memory impairment screen. Neurology. 1999;52(2):231–238
   PubMed Web of Science ®Google Scholar
• . Rabins PV, Lyketsos CG, Steele CD. Practical Dementia Care. New York, NY: Oxford University Press; 1999
   Google Scholar
• . Eschweiler GW, Leyhe T, Klöppel S, Hüll M. New developments in the diagnosis of dementia. Dtsch Arztebl Int. 2010;107(39):677–683
   PubMed Web of Science ®Google Scholar
• . Scheltens P. Imaging in Alzheimer's disease. Dialogues Clin Neurosci. 2009;11(2):191–199
   PubMedGoogle Scholar
• . Karow DS, McEvoy LK, Fennema-Notestine C, ; Alzheimer's Disease Neuroimaging Initiative. Relative capability of MR imaging and FDG PET to depict changes associated with prodromal and early Alzheimer disease. Radiology. 2010;256(3):932–942
   PubMed Web of Science ®Google Scholar
• . Padilla P, Górriz JM, Ramírez J, . Analysis of SPECT brain images for the diagnosis of Alzheimer's disease based on NMF for feature extraction. Neurosci Lett. 2010;479(3):192–196
   PubMed Web of Science ®Google Scholar
• . Reisberg B, Shulman MB, Torossian C, Leng L, Zhu W. Outcome over seven years of healthy adults with and without subjective cognitive impairment. Alzheimers Dement. 2010;6(1):11–24
   PubMed Web of Science ®Google Scholar
• . Villain N, Fouquet M, Baron JC, . Sequential relationships between grey matter and white matter atrophy and brain metabolic abnormalities in early Alzheimer's disease. Brain. 2010;133(11):3301–3314
   PubMedGoogle Scholar
• . Brewer JB. Fully-automated volumetric MRI with normative ranges: translation to clinical practice. Behav Neurol. 2009;21(1):21–28
   PubMed Web of Science ®Google Scholar
• . Jeong Y, Cho SS, Park JM, . 18F-FDG PET findings in frontotemporal dementia: an SPM analysis of 29 patients. J Nucl Med. 2005;46(2):233–239
   PubMed Web of Science ®Google Scholar
• . Morris JC, Roe CM, Xiong C, . APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010;67(1):122–131
   PubMed Web of Science ®Google Scholar
• . Simonsen AH, McGuire J, Hansson O, . Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment. Arch Neurol. 2007;64(3):366–370
   PubMedGoogle Scholar
• . Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006;5(3):228–234
   PubMed Web of Science ®Google Scholar
• . Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx. 2004;1(2):213–225
   PubMedGoogle Scholar
• . Verwey NA, van der Flier WM, Blennow K, . A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. Ann Clin Biochem. 2009;46(pt 3):235–240
   PubMed Web of Science ®Google Scholar
• . Teunissen CE, Verwey NA, Kester MI, van Uffelen K, Blankenstein MA. Standardization of Assay Procedures for Analysis of the CSF Biomarkers Amyloid β(1–42), Tau, and Phosphorylated Tau in Alzheimer's Disease: Report of an International Workshop. Int J Alzheimers Dis. 2010;2010:635053
   PubMedGoogle Scholar
• . Minoshima S, Foster NL, Petrie EC, Albin RL, Frey KA, Kuhl DE. Neuroimaging in dementia with Lewy bodies: metabolism, neurochemistry, and morphology. J Geriatr Psychiatry Neurol. 2002;15(4):200–209
   PubMed Web of Science ®Google Scholar
• . Cairns NJ, Bigio EH, Mackenzie IR, ; Consortium for Frontotemporal Lobar Degeneration. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol. 2007;114(1):5–22
   PubMed Web of Science ®Google Scholar
• . Jobst KA, Hindley NJ, King E, Smith AD. The diagnosis of Alzheimer's disease: a question of image? J Clin Psychiatry. 1994;55( suppl):22–31
   PubMed Web of Science ®Google Scholar
• . US Deptartment of Health and Human Services. CMS Manual System: Pub 100-03 Medicare National Coverage Determinations, Transmittal 120. https://www.cms.gov/transmittals/downloads/R120NCD.pdf. Published May 6, 2010. Accessed January 28, 2011
   Google Scholar
• . Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer's disease using three-dimensional stereo-tactic surface projections of fluorine-18-FDG PET. J Nucl Med. 1995;36(7):1238–1248
   PubMed Web of Science ®Google Scholar
• . Scheltens P, Korf ES. Contribution of neuroimaging in the diagnosis of Alzheimer's disease and other dementias. Curr Opin Neurol. 2000;13(4):391–396
   PubMedGoogle Scholar
• . Jobst KA, Barnetson LP, Shepstone BJ. Accurate prediction of histologically confirmed Alzheimer's disease and the differential diagnosis of dementia: the use of NINCDS-ADRDA and DSM-III-R criteria, SPECT, X-ray CT, and Apo E4 in medial temporal lobe dementias. Oxford Project to Investigate Memory and Aging. Int Psychogeriatr. 1998;10(3):271–302
   PubMedGoogle Scholar
• . Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol. 1997;42(1)85–94
   PubMed Web of Science ®Google Scholar
• . Dougall NJ, Bruggink S, Ebmeier KP. Systematic review of the diagnostic accuracy of 99 mTc-HMPAO-SPECT in dementia. Am J Geriatr Psychiatry. 2004;12(6):554–570
   PubMed Web of Science ®Google Scholar
• . Borghesani PR, DeMers SM, Manchanda V, Pruthi S, Lewis DH, Borson S. Neuroimaging in the clinical diagnosis of dementia: observations from a memory disorders clinic. J Am Geriatr Soc. 2010;58(8):1453–1458
   PubMed Web of Science ®Google Scholar
• . Ishii K, Minoshima S. PET is better than perfusion SPECT for early diagnosis of Alzheimer's disease—for. Eur J Nucl Med Mol Imaging. 2005;32(12):1463–1465
   PubMed Web of Science ®Google Scholar
• . Ishiwata A, Sakayori O, Minoshima S, Mizumura S, Kitamura S, Katayama Y. Preclinical evidence of Alzheimer changes in progressive mild cognitive impairment: a qualitative and quantitative SPECT study. Acta Neurol Scand. 2006;114(2):91–96
   PubMed Web of Science ®Google Scholar
• . Uchida Y, Minoshima S, Okada S, Kawata T, Ito H. Diagnosis of dementia using perfusion SPECT imaging at the patient's initial visit to a cognitive disorder clinic. Clin Nucl Med. 2006;31(12):764–773
   PubMed Web of Science ®Google Scholar
• . Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med. 2001;42( 5 suppl):1S–93S
   PubMed Web of Science ®Google Scholar
• . Zakzanis KK, Graham SJ, Campbell Z. A meta-analysis of structural and functional brain imaging in dementia of the Alzheimer's type: a neuroimaging profile. Neuropsychol Rev. 2003;13(1):1–18
   PubMed Web of Science ®Google Scholar
• . Minoshima S. Imaging Alzheimer's disease: clinical applications. Neuroimaging Clin N Am. 2003;13(4):769–780
   PubMed Web of Science ®Google Scholar
• . Silverman DH, Alavi A. PET imaging in the assessment of normal and impaired cognitive function. Radiol Clin North Am. 2005;43(1):67–77, x
   PubMed Web of Science ®Google Scholar
• . O'Brien JT, Colloby SJ, Pakrasi S, . Nicotinic alpha4beta2 receptor binding in dementia with Lewy bodies using 123I-5IA-85380 SPECT demonstrates a link between occipital changes and visual hallucinations. Neuroimage. 2008;40(3):1056–1063
   PubMed Web of Science ®Google Scholar
• . Minoshima S, Foster NL, Sima AA, Frey KA, Albin RL, Kuhl DE. Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol. 2001;50(3):358–365
   PubMed Web of Science ®Google Scholar
• . Imamura T, Ishii K, Sasaki M, . Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease: a comparative study using positron emission tomography. Neurosci Lett. 1997;235(1–2):49–52
   PubMed Web of Science ®Google Scholar
• . Kantarci K, Jack CR Jr. Neuroimaging in Alzheimer disease: an evidence-based review. Neuroimaging Clin N Am. 2003;13(2):197–209
   PubMed Web of Science ®Google Scholar
• . Walker Z, Costa DC, Walker RW, . Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry. 2002;73(2):134–140
   PubMed Web of Science ®Google Scholar
• . Bonte FJ, Harris TS, Roney CA, Hynan LS. Differential diagnosis between Alzheimer's and frontotemporal disease by the posterior cingulate sign. J Nucl Med. 2004;45(5):771–774
   PubMed Web of Science ®Google Scholar
• . Diehl-Schmid J, Grimmer T, Drzezga A, . Decline of cerebral glucose metabolism in frontotemporal dementia: a longitudinal 18F-FDG-PET-study. Neurobiol Aging. 2007;28(1):42–50
   PubMed Web of Science ®Google Scholar
• . US Food and Drug Administration; US Department of Health and Human Services. FDA approved drug products. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/. Accessed January 28, 2011
   Google Scholar
• . Wong DF, Rosenberg PB, Zhou Y, . In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med. 2010;51(6):913–920
   PubMed Web of Science ®Google Scholar
• . Okamura N, Yanai K. Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease. IDrugs. 2010;13(12):890–899
   PubMedGoogle Scholar
• . Klunk WE, Engler H, Nordberg A, . Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306–319
   PubMed Web of Science ®Google Scholar
• . Rowe CC, Ackerman U, Browne W, . Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008;7(2):129–135
   PubMed Web of Science ®Google Scholar
• . US Food and Drug Administration; US Department of Health and Human Services. FDA advisory committee briefing document, NDA #202-008, florbetapir F18 injection. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/UCM240266.pdf. Accessed January 28, 2011
   Google Scholar
• . Ishii K, Kanda T, Uemura T, . Computer-assisted diagnostic system for neurodegenerative dementia using brain SPECT and 3D-SSP. Eur J Nucl Med Mol Imaging. 2009;36(5):831–840
   PubMed Web of Science ®Google Scholar